The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
Open accessAbstract
Ceruloplasmin is an iron-export ferroxidase that is abundant in plasma and also expressed in glia. We found a ∼80% loss of ceruloplasmin ferroxidase activity in the substantia nigra of idiopathic Parkinson disease (PD) cases, which could contribute to the pro-oxidant iron accumulation that characterizes the pathology. Consistent with a role for ceruloplasmin in PD etiopathogenesis, ceruloplasmin knockout mice developed parkinsonism that was rescued by iron chelation. Additionally, peripheral infusion of ceruloplasmin attenuated neurodegeneration and nigral iron elevation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model for PD. These findings show, in principle, that intravenous ceruloplasmin may have therapeutic potential in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ceruloplasmin dysfunction might be associated with Parkinson’s disease.135,136”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
C ERULOPLASMIN M ETABOLISM AND F UNCTION
Hellman, N. E., & Gitlin, J. D. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.012502.114457 · Cited by 954
Duce, J. A., Tsatsanis, A., Cater, M. A., James, S., Robb, E. L., Wikhe, K., Leong, S. L., Perez, K. A., Johanssen, T., Greenough, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.08.014 · Cited by 695
Self-citationThe possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum.
Osaki, S., Johnson, D. A., & Frieden, E. (1966) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)96527-0 · Cited by 679
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Self-citationTau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594
Self-citationThe A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity
Golts, N., Petrucelli, L., Hardy, J., Lee, J. M., Farer, M., & Wolozin, B. L. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06048.2000 · Cited by 550
Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury
Patel, B. N., Dunn, R. J., Jeong, S. Y., Zhu, Q., Julien, J.-P., & David, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06578.2002 · Cited by 379
Individual dopaminergic neurons show raised iron levels in Parkinson disease
Oakley, A. E., Collingwood, J. F., Dobson, J., Love, G., Perrott, H. R., Edwardson, J. A., Elstner, M., & Morris, C. M. (2007) · Neurology · doi:10.1212/01.wnl.0000262033.01945.9a · Cited by 273
Sequestration of iron by Lewy bodies in Parkinson's disease
Castellani, R. J., Siedlak, S. L., Perry, G., & Smith, M. A. (2000) · Acta Neuropathologica · doi:10.1007/s004010050001 · Cited by 265
The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism
Rozas, G., López-Martín, M. E., Guerra, M. J., & Labandeira-García, J. L. (1998) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(98)00078-8 · Cited by 225
Boll, M.-C., Alcaraz-Zubeldia, M., Montes, S., & Rios, C. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9610-3 · Cited by 173
The Neurological Presentation of Ceruloplasmin Gene Mutations
McNeill, A., Pandolfo, M., Kuhn, J., Shang, H., & Miyajima, H. (2008) · European Neurology · doi:10.1159/000148691 · Cited by 163
Klomp, L. W. J. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.12.1989 · Cited by 161
Jin, L., Wang, J., Zhao, L., Jin, H., Fei, G., Zhang, Y., Zeng, M., & Zhong, C. (2010) · Brain · doi:10.1093/brain/awq319 · Cited by 129
Olivieri, S., Conti, A., Iannaccone, S., Cannistraci, C. V., Campanella, A., Barbariga, M., Codazzi, F., Pelizzoni, I., Magnani, G., Pesca, M., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3768-11.2011 · Cited by 125
Copper, Ceruloplasmin, Superoxide Dismutase and Iron Parameters in Parkinson's Disease
Tórsdóttir, G., Kristinsson, J., Sveinbjörnsdóttir, S., Snædal, J., & Jøhannesson, T. (1999) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1999.tb02015.x · Cited by 115
Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease
Hochstrasser, H., Bauer, P., Walter, U., Behnke, S., Spiegel, J., Csoti, I., Zeiler, B., Bornemann, A., Pahnke, J., Becker, G., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000144276.29988.c3 · Cited by 111
Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease
Boll, M.-C., Sotelo, J., Otero, E., Alcaraz-Zubeldia, M., & Rios, C. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00221-9 · Cited by 92
Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY‐5Y cells
Molina‐Holgado, F., Gaeta, A., Francis, P. T., Williams, R. J., & Hider, R. C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05332.x · Cited by 84
Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s disease
Bharucha, K. J., Friedman, J. H., Vincent, A. S., & Ross, E. D. (2008) · Journal of Neurology · doi:10.1007/s00415-009-0063-7 · Cited by 62
Nigral iron deposition occurs across motor phenotypes of Parkinson’s disease
Jin, L., Wang, J., Jin, H. M., Fei, G.-J., Zhang, Y., Chen, W., Zhao, L., Zhao, N., Sun, X., Zeng, M., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03658.x · Cited by 49
Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: A follow-up study
Tórsdóttir, G., Sveinbjörnsdóttir, S., Kristinsson, J., Snædal, J., & Jøhannesson, T. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.10.015 · Cited by 38
Martínez-Hernández, R., Montes, S., Higuera-Calleja, J., Yescas, P., Boll, M.-C., Diaz-Ruiz, A., & Rios, C. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0535-x · Cited by 34
Flagged first, then by citations
1 of the 25 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819
Wilson's disease and other neurological copper disorders
Bandmann, O., Weiss, K. H., & Kaler, S. G. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70190-5 · Cited by 1,067
Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease
Trist, B. G., Hare, D. J., & Double, K. L. (2019) · Aging Cell · doi:10.1111/acel.13031 · Cited by 778
Tau-mediated iron export prevents ferroptotic damage after ischemic stroke
Tuo, Q.-Z., Lei, P., Jackman, K. A., Li, X.-L., Xiong, H., Li, X.-L., Liuyang, Z.-Y., Roisman, L. C., Zhang, S.-T., Ayton, S., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.171 · Cited by 715
Self-citationInteractions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
Metadata
- Authors
- Ayton, S., Lei, P., Duce, J. A., Wong, B. X. W., Sedjahtera, A., Adlard, P. A., Bush, A. I., & Finkelstein, D. I.
- Affiliations
- Florey Institute of Neuroscience and Mental Health (AU)
- The University of Melbourne (AU)
- Corresponding author
- Bush, Ashley I.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2013-02-19
- Volume
- 73
- Issue
- 4
- Pages
- 554-559
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2148573575
- Cited by
- 264
- References
- 25
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 22 · 2023: 22 · 2022: 23 · 2021: 21 · 2020: 19 · 2019: 16 · 2018: 17 · 2017: 25 · 2016: 18 · 2015: 23 · 2014: 21 · 2013: 8
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- ceruloplasmin, Parkinson's disease, ferroxidase activity, iron accumulation, substantia nigra, iron chelation, parkinsonism, neurodegeneration, MPTP mouse model
- MeSH terms
- Deferiprone, Aged, Animals, Ceruloplasmin, Disease Models, Animal, Female, Humans, Iron Chelating Agents, Male, Parkinson Disease, Pyridones, Substantia Nigra, Dopamine Agents, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Case-Control Studies, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
